GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frequency Therapeutics Inc (NAS:FREQ) » Definitions » 5-Year Yield-on-Cost %

Frequency Therapeutics (Frequency Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of May. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Frequency Therapeutics 5-Year Yield-on-Cost %?

Frequency Therapeutics's yield on cost for the quarter that ended in Jun. 2023 was 0.00.


The historical rank and industry rank for Frequency Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



FREQ's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.895
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Frequency Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Frequency Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frequency Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Frequency Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Frequency Therapeutics's 5-Year Yield-on-Cost % falls into.



Frequency Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Frequency Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Frequency Therapeutics  (NAS:FREQ) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Frequency Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Frequency Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Frequency Therapeutics (Frequency Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
75 Hayden Avenue, Suite 300, Lexington, MA, USA, 02421
Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss.
Executives
Richard J. Mitrano officer: VP Finance & Operations C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
David L. Lucchino director, officer: President and CEO C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Christopher R. Loose officer: Chief Scientific Officer C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Quentin Mccubbin officer: Chief Manufacturing Officer C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Wendy S Arnold officer: Chief People Officer 19 PRESIDENTIAL WAY, SUITE 203, WOBURN MA 01801
Carl Lebel officer: Chief Development Officer 23256 MARIPOSA DE ORO, MALIBU CA 90265
Peter P. Pfreundschuh officer: Chief Financial Officer C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Michael Bookman officer: General Counsel and Secretary C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Joel S Marcus director, 10 percent owner C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Marc A Cohen director 1000 WILSON BLVD. #1800, ARLINGTON VA 22209
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Alexandria Venture Investments, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101

Frequency Therapeutics (Frequency Therapeutics) Headlines